Everything we've seen

1. ·Nov 15, 11:30 AMstreamnews

   Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

   Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

2. ·Nov 15, 11:30 AMstreamnews

   Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

   KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

3. ·Nov 15, 11:15 AMstreamnews

   Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

   Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

4. ·Nov 15, 11:15 AMstreamnews

   Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

   KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

5. ·Nov 15, 11:00 AMstreamnews

   Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

   Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

6. ·Nov 15, 11:00 AMstreamnews

   Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

   KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

7. ·Nov 15, 10:45 AMstreamnews

   Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

   Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

8. ·Nov 15, 10:45 AMstreamnews

   Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

   KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

9. ·Nov 15, 10:30 AMstreamnews

   Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

   Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

10. ·Nov 15, 10:30 AMstreamnews

    Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

    KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

11. ·Nov 15, 10:15 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

12. ·Nov 15, 10:15 AMstreamnews

    Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

    KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

13. ·Nov 15, 10:00 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

14. ·Nov 15, 10:00 AMstreamnews

    Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

    KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

15. ·Nov 15, 9:45 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

16. ·Nov 15, 9:45 AMstreamnews

    Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

    KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

17. ·Nov 15, 9:30 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

18. ·Nov 15, 9:30 AMstreamnews

    Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

    KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

19. ·Nov 15, 9:15 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

20. ·Nov 15, 9:00 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

21. ·Nov 15, 8:45 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

22. ·Nov 15, 8:30 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

23. ·Nov 15, 8:15 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

24. ·Nov 15, 8:00 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

25. ·Nov 15, 7:45 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

26. ·Nov 15, 7:30 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

27. ·Nov 15, 7:15 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

28. ·Nov 15, 7:00 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

29. ·Nov 15, 6:45 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

30. ·Nov 15, 6:30 AMstreamnews

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

31. ❖Nov 14, 7:25 AMnewsvia finnhub

    Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

    The stock has climbed more than 40% in one year.

32. ❖Nov 13, 8:08 PMnewsvia finnhub

    Could You Have Held Glaukos Stock Through Its Falls?

    For questions about this article or underlying research, email help@trefis.com.

33. ❖Nov 13, 10:41 AMnewsvia finnhub

    Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

    KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

34. ❖Nov 13, 9:01 AMnewsvia finnhub

    Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

    Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.

35. ❖Nov 12, 5:00 PMnewsvia finnhub

    POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

    Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma v

36. ❖Nov 12, 12:15 PMnewsvia finnhub

    If You Invested $1000 In Regeneron Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today

    Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 8.79% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron Pharmaceuticals has a market

37. ❖Nov 12, 11:21 AMnewsvia finnhub

    REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

    Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.

38. ❖Nov 12, 10:13 AMnewsvia finnhub

    What Moved Alnylam Stock?

    For questions about this article or underlying research, email help@trefis.com.

39. ❖Nov 12, 3:11 AMnewsvia finnhub

    Regeneron Pharmaceuticals (REGN) Reports Early MASLD Trial Data With 62% Liver Fat Normalization

    Regeneron Pharmaceuticals (NasdaqGS:REGN) reported first in human data for CIDEBsiRNA, a liver targeted siRNA candidate for MASLD. The early study showed sustained normalization of liver fat and improvement in liver injury markers in treated participants. Results were presented at a major medical meeting and published in a top tier journal, extending Regeneron's RNAi ambitions into liver disease. The CIDEBsiRNA readout comes against a broader context that our research on Regeneron has been...

40. !Nov 11, 5:00 PMsignal

    Agent 1 — Immutable — insufficient_capital

41. ?Nov 11, 5:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 2: close $959.69 > MA150 $737.84 (+30.1%), MA rising, 3.2% off 52w high, vol 1.03× avg

42. ❖Nov 11, 10:38 AMnewsvia finnhub

    What Will Decide Vertex Stock Over The Next Six Months?

    For questions about this article or underlying research, email help@trefis.com.

43. ❖Nov 11, 8:36 AMnewsvia finnhub

    S&P 500 Premarket Movers: Gainers and Losers Ahead of the Open

    S&P 500 premarket movers: COHR, LITE, STX, MRVL and WDC lead gainers, while ACGL, CLX, ABNB and REGN slip ahead of the opening bell.

44. ❖Nov 11, 6:04 AMnewsvia finnhub

    iShares Biotechnology ETF (IBB) Adds Gilead and Amgen on Nov. 9

    The $11.34 billion fund bought $230.1 million of stock on Monday, Nov. 9, lifting 231 positions and trimming none.

45. ❖Nov 11, 4:02 AMnewsvia finnhub

    Brightview Posts Downbeat Q4 Results, Joins Astronics, Spire Global And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

    U.S. futures rose, but BrightView plunged 17.7% after missing earnings and sales estimates; Lightwave Logic and others also fell premarket.

46. ❖Nov 10, 1:39 PMnewsvia finnhub

    Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction

    Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.

47. ❖Nov 10, 1:17 PMnewsvia finnhub

    Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later?

    One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which one earns a spot in a retirement account.

48. ❖Nov 10, 12:15 PMnewsvia finnhub

    Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%

    Regeneron Pharmaceuticals (NASDAQ:REGN) is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced liver fat, executives said during an investor event. The company said its phase 2b study in patien

49. ❖Nov 10, 11:01 AMnewsvia finnhub

    Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript

    Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH November 10, 2026 8:30 AM ESTCompany ParticipantsRyan...

50. ❖Nov 10, 10:00 AMnewsvia finnhub

    Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD

    CAMBRIDGE, Mass., November 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that we

51. ❖Nov 10, 8:47 AMnewsvia finnhub

    3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them

    Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all. Coverage, not yield, tells the real story.

52. ❖Nov 10, 8:15 AMnewsvia finnhub

    Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

    Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

53. ❖Nov 10, 7:00 AMnewsvia finnhub

    Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults with Fibrodysplasia Ossificans Progressiva

    FRISCO, Texas, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today that it was selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron’s FDA-approved product to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Approved August 19, 2026, Pasa

54. ❖Nov 10, 6:02 AMnewsvia finnhub

    Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients

    Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeksData shared in oral presentation at AASLD The Liver Meeting® and

55. ❖Nov 10, 5:34 AMnewsvia finnhub

    Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH - Slideshow

    2026-11-10. The following slide deck was published by Regeneron Pharmaceuticals, Inc.

56. ?Nov 9, 2:51 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is up 2.60% intraday, a meaningful move suggesting real conviction and size. However, several factors temper enthusiasm for strong continuation. Only 55 minutes remain until the forced close, which significantly limits the runway for further gains toward the +3% profit target — REGN would need to reach ~$931.47 from ~$927.88, an additional ~0.39%. The sole headline is a generic market research report on gene therapy for hearing loss that broadly mentions Regeneron among several companies — this is not a catalyst specific to REGN and likely did not drive today's move. The macro backdrop (elevated mortgage rates at 1.9σ above trend) is not directly relevant to biotech/pharma. With no clear catalyst identified, the move could represent broader biotech sector rotation or block flow. With 55 minutes remaining, the position has limited time to reach the profit target but also limited downside exposure given tight stops. The base case is mild continuation or consolidation near current levels — no strong reason to expect a reversal, but also no compelling reason to assign high continuation probability. Rating at the floor of the action threshold given time constraint and lack of specific catalyst.

57. !Nov 9, 2:51 PMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    REGN is up 2.60% intraday, a meaningful move suggesting real conviction and size. However, several factors temper enthusiasm for strong continuation. Only 55 minutes remain until the forced close, which significantly limits the runway for further gains toward the +3% profit target — REGN would need to reach ~$931.47 from ~$927.88, an additional ~0.39%. The sole headline is a generic market research report on gene therapy for hearing loss that broadly mentions Regeneron among several companies — this is not a catalyst specific to REGN and likely did not drive today's move. The macro backdrop (elevated mortgage rates at 1.9σ above trend) is not directly relevant to biotech/pharma. With no clear catalyst identified, the move could represent broader biotech sector rotation or block flow. With 55 minutes remaining, the position has limited time to reach the profit target but also limited downside exposure given tight stops. The base case is mild continuation or consolidation near current levels — no strong reason to expect a reversal, but also no compelling reason to assign high continuation probability. Rating at the floor of the action threshold given time constraint and lack of specific catalyst.

58. ❖Nov 9, 9:31 AMnewsvia finnhub

    Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

    Profiles Regeneron, Eli Lilly, Sensorion, Astellas Pharma and BridgeBio, covering hearing-loss gene therapies, pipelines, innovation and market activity.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Gene Therapy For Hearing Loss Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global gene therapy for hearing loss market is experiencing rapid expansion, supported by advances in molecular genetics, regenerative medicine and targeted treatment development. The market

59. ❖Nov 9, 7:51 AMnewsvia finnhub

    Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?

    Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.

60. ❖Nov 8, 4:00 PMnewsvia finnhub

    CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

    Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data from first-in-human trial were shared in oral presentation at AASLD The Liver Meeting® and simultaneously published in The New England Journal of Medicine Regeneron to host virtual “Regeneron Roundtable” investor event to discuss its MASH pipeline programs on Tuesday, November 10 at 8:30 a.m. ET TARRYTOWN, N.Y., Nov. 08, 2026 (GLOBE NEWSWIRE) -- R

61. ❖Nov 8, 9:10 AMnewsvia finnhub

    Regeneron Pharmaceuticals (REGN) Extends BARDA Deal As Libtayo Long Term Data Holds Up

    Regeneron Pharmaceuticals (NasdaqGS:REGN) reported new long-term Phase 3 data for Libtayo in high-risk cutaneous squamous cell carcinoma. The trial readout highlighted sustained disease-free and overall survival outcomes in patients treated with Libtayo adjuvant therapy despite high crossover rates. Regeneron expanded its U.S. government agreement with BARDA for additional Inmazeb supply to support infectious disease preparedness efforts. The Libtayo survival data and extended Inmazeb BARDA...

62. ❖Nov 6, 12:24 PMnewsvia finnhub

    Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

    NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.

63. ❖Nov 6, 6:01 AMnewsvia finnhub

    Huda Y Zoghbi At Regeneron Pharmaceuticals Executes Options Exercise, Realizing $3.88M

    Highlighted on November 5, it was unveiled in an SEC filing that Zoghbi, Director at Regeneron Pharmaceuticals (NASDAQ:REGN), executed a significant transaction involving the exercise of company stock options. What

64. ?Nov 5, 1:46 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down ~1.93% today, which is a moderate but not dramatic intraday move. The headline available is a consortium announcement (Mary Tyler Moore Vision Initiative) that is mildly positive for REGN sentiment, suggesting no major negative catalyst is driving the sell-off — the decline may be more flow/macro driven than news-driven. The macro context shows elevated Fed Funds Rate (3.88, 2.1σ above trend), which is a headwind for growth/biotech names like REGN, potentially sustaining some selling pressure. However, with 119 minutes remaining until the forced close, there is meaningful time for either continuation or reversal. The move is below the 2% threshold where momentum tends to be more self-sustaining, and the mildly positive news headline could attract dip buyers, creating a fade risk. The absence of a clear negative catalyst and the presence of a constructive news item tilt the balance slightly toward reversal rather than continuation. Probability of downside continuation assessed just below 0.5, favoring no trade.

65. !Nov 5, 1:46 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down ~1.93% today, which is a moderate but not dramatic intraday move. The headline available is a consortium announcement (Mary Tyler Moore Vision Initiative) that is mildly positive for REGN sentiment, suggesting no major negative catalyst is driving the sell-off — the decline may be more flow/macro driven than news-driven. The macro context shows elevated Fed Funds Rate (3.88, 2.1σ above trend), which is a headwind for growth/biotech names like REGN, potentially sustaining some selling pressure. However, with 119 minutes remaining until the forced close, there is meaningful time for either continuation or reversal. The move is below the 2% threshold where momentum tends to be more self-sustaining, and the mildly positive news headline could attract dip buyers, creating a fade risk. The absence of a clear negative catalyst and the presence of a constructive news item tilt the balance slightly toward reversal rather than continuation. Probability of downside continuation assessed just below 0.5, favoring no trade.

66. ?Nov 5, 11:25 AMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $922.74 > MA150 $733.75 (+25.8%), MA rising, 7.0% off 52w high, vol 0.02× avg

67. ❖Nov 5, 11:06 AMnewsvia finnhub

    Mary Tyler Moore Vision Initiative Welcomes Regeneron and Adaptive Sensory Technology to Its Consortium

    The Mary Tyler Moore Vision Initiative (MTM Vision) today announced that Regeneron Pharmaceuticals, Inc. has joined the MTM Vision Consortium as a founding member and Adaptive Sensory Technology as a device company member.

68. ?Nov 5, 10:10 AMdecisionconsidered

    Agent 1 — Immutable — considered

    Stage 2: close $941.49 > MA150 $733.87 (+28.3%), MA rising, 5.1% off 52w high, vol 0.01× avg

69. ❖Nov 5, 6:01 AMnewsvia finnhub

    Strategic Exercise: Christine A Poon Decides To Exercise Options Worth $4.39M At Regeneron Pharmaceuticals

    Disclosed in a recent SEC filing on November 4, Poon, Board Member at Regeneron Pharmaceuticals (NASDAQ:REGN), made a noteworthy transaction involving the exercise of company stock options. What Happened: A notable Form

70. ❖Nov 5, 6:01 AMnewsvia finnhub

    At Regeneron Pharmaceuticals, George L Sing Chooses To Exercise Options, Resulting In $8.53M

    A significant insider transaction involving the exercise of company stock options was reported on November 4, by George L Sing, Board Member at Regeneron Pharmaceuticals (NASDAQ:REGN), as per the latest SEC filing. What

71. ❖Nov 5, 5:36 AMnewsvia finnhub

    Is Regeneron Stock Riskier Than It Looks?

    For questions about this article or underlying research, email help@trefis.com.

72. ❖Nov 4, 5:22 PMnewsvia finnhub

    Is Regeneron Stock Increasing Your Market Risk?

    For questions about this article or underlying research, email help@trefis.com.

73. ❖Nov 4, 3:59 PMnewsvia finnhub

    Was There Any Sign Regeneron Stock Would Run?

    For questions about this article or underlying research, email help@trefis.com.

74. ?Nov 4, 1:41 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 3.19% today, a meaningful move suggesting real institutional selling pressure. However, several factors temper the continuation thesis: (1) The headline 'Why Regeneron (REGN) Might be Well Poised for a Surge' published mid-session could attract dip buyers and slow downside momentum. (2) The Moderna mRNA therapy headline is modestly negative for REGN as a competitive signal in oncology, but the effect is indirect. (3) Macro context shows elevated Fed Funds rate (3.88, 2.1σ above trend), which is a headwind for high-multiple biotech broadly — this is mildly supportive of continued selling in the sector. (4) With 125 minutes remaining there is sufficient time for continuation, but also enough time for a late-session bounce or mean reversion on a stock that hasn't shown a clear catalyst-driven gap. (5) No strong reversal signals are apparent, and the base rate for a 3%+ intraday move continuing into the close is modestly positive. Overall, the move is real and the macro backdrop is modestly unfavorable for REGN, but the bullish analyst note and absence of a hard negative catalyst keep this a marginal continuation read rather than a high-conviction one.

75. !Nov 4, 1:41 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 3.19% today, a meaningful move suggesting real institutional selling pressure. However, several factors temper the continuation thesis: (1) The headline 'Why Regeneron (REGN) Might be Well Poised for a Surge' published mid-session could attract dip buyers and slow downside momentum. (2) The Moderna mRNA therapy headline is modestly negative for REGN as a competitive signal in oncology, but the effect is indirect. (3) Macro context shows elevated Fed Funds rate (3.88, 2.1σ above trend), which is a headwind for high-multiple biotech broadly — this is mildly supportive of continued selling in the sector. (4) With 125 minutes remaining there is sufficient time for continuation, but also enough time for a late-session bounce or mean reversion on a stock that hasn't shown a clear catalyst-driven gap. (5) No strong reversal signals are apparent, and the base rate for a 3%+ intraday move continuing into the close is modestly positive. Overall, the move is real and the macro backdrop is modestly unfavorable for REGN, but the bullish analyst note and absence of a hard negative catalyst keep this a marginal continuation read rather than a high-conviction one.

76. ❖Nov 4, 11:41 AMnewsvia finnhub

    Moderna Soars 8% on Early Multiple Myeloma Data for Its Three-in-One mRNA Therapy

    Key TakeawaysModerna shares jumped 8% after its myeloma therapy, mRNA-2808, showed four confirmed responses among 11 heavily pretreated patients. The data shows Moderna’s mRNA can get the body to make three cancer drugs at once, though it’s years from challenging Johnson & Johnson, Pfizer and Regeneron.

77. ❖Nov 4, 11:20 AMnewsvia finnhub

    Why Regeneron (REGN) Might be Well Poised for a Surge

    Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

78. ❖Nov 4, 10:40 AMnewsvia finnhub

    REGN vs. ILMN: Which Stock Is the Better Value Option?

    REGN vs. ILMN: Which Stock Is the Better Value Option?

79. ❖Nov 4, 3:29 AMnewsvia finnhub

    Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...'

    Drugmaker executives doubt AI will cure disease soon, saying biology is too complicated.

80. !Nov 3, 5:00 PMsignal

    Agent 1 — Immutable — insufficient_capital

81. ?Nov 3, 5:00 PMdecisionconsidered

    Agent 2 — Adaptive — entry

    [not executed — reserve_floor_or_cash] Stage 2: close $974.25 > MA150 $731.66 (+33.2%), MA rising, 0.1% off 52w high, vol 1.18× avg

82. ❖Nov 3, 1:12 PMnewsvia finnhub

    BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well

    Bayer's Q3 earnings and revenues miss estimates, but strong growth in Nubeqa and Kerendia boosts pharma performance and lifts 2026 EBITDA guidance.

83. ❖Nov 3, 7:52 AMnewsvia finnhub

    Regeneron Pharmaceuticals (NASDAQ:REGN) Looks Undervalued Under the Decent Value Framework

    Regeneron fits the Decent Value screen: cheap vs peers and S&P 500, strong health and profitability, and moderate growth support a quality-at-a-fair-price case.

84. ❖Nov 3, 3:06 AMnewsvia finnhub

    UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC’s ‘Final Trades’

    CNBC traders picked RSP, Cleveland-Cliffs, UnitedHealth and Regeneron; REGN surged after strong Q3 earnings, while RSP also gained.

85. ❖Nov 3, 12:40 AMnewsvia finnhub

    ValuEngine Weekly Market Commentary

    US equity markets remained under pressure this week, with technology and growth-oriented stocks extending their declines while value, defensive, and cyclical sectors showed resilience.

86. ❖Nov 2, 9:50 PMnewsvia finnhub

    Regeneron Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation

    2026-11-03. The following slide deck was published by Regeneron Pharmaceuticals, Inc.

87. !Nov 2, 5:00 PMsignal

    Agent 1 — Immutable — insufficient_capital

88. ?Nov 2, 5:00 PMdecisionconsidered

    Agent 2 — Adaptive — entry

    [not executed — reserve_floor_or_cash] Stage 2: close $961.43 > MA150 $730.32 (+31.6%), MA rising, 1.3% off 52w high, vol 2.26× avg

89. ❖Nov 2, 4:05 PMnewsvia finnhub

    Regeneron Announces Investor Conference Presentations

    TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT (9:00 a.m. ET) on Tuesday, November 17, 20269th Annual Evercore Healthcare Conference at 1:45 p.m. ET on Tuesday, December 1, 2026Citi’s 2026 Global Healthcare Conference at 9:40 a.m. ET on Wednesday, December 2, 2026 The sessions may be accessed from the "Investors & Media" page

90. ❖Nov 2, 2:33 PMnewsvia finnhub

    REGN Q3 deep dive: pipeline progress and core brands drive outperformance

    Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 36.3% year on year to $5.12 billion. Its non-GAAP profit of $20.07 per share was 23.5% above analysts’ consensus estimates.

91. ❖Nov 2, 1:05 PMnewsvia finnhub

    S&P 500 Unusual Volume Movers for Nov. 2, 2026

    Nov. 2, 2026 scan of S&P 500 unusual-volume stocks: Reddit, West Pharmaceutical, Regeneron, Estée Lauder and IDEXX traded above their 50-day average volume.

92. ❖Nov 2, 11:40 AMnewsvia finnhub

    Regeneron's 'Strong Commercial' Q3 Underscores Core Business Health, RBC Capital Markets Says

    Regeneron Pharmaceuticals' (REGN) "strong commercial" Q3 underscores the health of its core business

93. ❖Nov 2, 10:58 AMnewsvia finnhub

    Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

    Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.

94. ❖Nov 2, 9:40 AMnewsvia finnhub

    Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

    Bernstein analyst Jeffrey Walch maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $756 to $812.

95. ▣Nov 1, 7:00 PMjournaltarget

    Agent 4 — Dip Buyer (Frozen) closed long 1 @ $961.43 (+$203.18)

    Target hit: close $961.43 ≥ target $859.34

96. ✓Oct 30, 6:21 PMdecisionacted

    Agent 20 — SIR Price/Volume — buy

    [cluster_break_up] For the 19 sessions from 2026-10-05 through 2026-10-29, REGN traced a tight, slowly rising cluster between $726 and $819 on uniformly subdued volume (daily range roughly 424K–878K, trailing 20-day ADV ~633K) — a classic SIR low-volume consolidation band. On 2026-10-30, the ticker exploded to $927.86 (+13.32%) on 5.2M shares — a volume z-score of 35.81 versus the prior mean, representing roughly 8× the ADV and dwarfing even the cluster's heaviest day (878K on 2026-10-14). In SIR 2-D space, the path shot sharply up-and-right in a single session, breaking cleanly above the entire 19-day price cluster, which is the archetypal cluster_break_up signature: fresh, overwhelming demand absorbing the float and repricing the issue in one decisive move. Risks: The primary risk is single-bar exhaustion — the methodology cautions that an unprecedented volume spike at a price extreme can also mark a climactic blow-off, and multi-session confirmation (continued up-day volume dominance above the breakout level, ideally near or above $900) is needed to distinguish sustained accumulation from a one-day event-driven squeeze. A failure to hold above the prior cluster ceiling (~$820) on the next 2–3 sessions, or a reversion on expanding down-day volume, would invalidate the bullish read entirely.

97. ?Oct 23, 11:15 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is down 1.62% with no attributable news catalyst visible. The move is modest — below the 2-5% threshold that would signal strong institutional conviction — making it harder to classify as a high-confidence momentum continuation. With 270 minutes remaining (roughly 4.5 hours, essentially the full afternoon session), there is ample time for the move to either extend or mean-revert. The macro backdrop (T10Y2Y at 0.31, 1.6σ below trend) favors defensives in a bear-flattening regime, which is a mild positive for large-cap biopharma like REGN — suggesting some modest headwind against further downside rather than a tailwind. No headlines to confirm a fundamental driver. The combination of a sub-2% move, no news, and a macro context that is mildly supportive of the sector produces a borderline read. Applying the system's default of taking borderline reads, probability is set at 0.50 for continuation to the downside — the weakest possible trigger, reflecting genuine uncertainty rather than conviction.

98. !Oct 23, 11:15 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    REGN is down 1.62% with no attributable news catalyst visible. The move is modest — below the 2-5% threshold that would signal strong institutional conviction — making it harder to classify as a high-confidence momentum continuation. With 270 minutes remaining (roughly 4.5 hours, essentially the full afternoon session), there is ample time for the move to either extend or mean-revert. The macro backdrop (T10Y2Y at 0.31, 1.6σ below trend) favors defensives in a bear-flattening regime, which is a mild positive for large-cap biopharma like REGN — suggesting some modest headwind against further downside rather than a tailwind. No headlines to confirm a fundamental driver. The combination of a sub-2% move, no news, and a macro context that is mildly supportive of the sector produces a borderline read. Applying the system's default of taking borderline reads, probability is set at 0.50 for continuation to the downside — the weakest possible trigger, reflecting genuine uncertainty rather than conviction.

99. ?Oct 20, 2:46 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    REGN is up 2.12% intraday, a meaningful move suggesting real institutional flow. However, several factors temper continuation confidence: (1) Only 60 minutes remain until the forced close, limiting runway for the +3% target to be reached from current levels (would need ~+0.9% more from $798.60 to ~$805.60+). (2) The sole headline references a rare-disease foundation story that is tangentially related to REGN's oncology exposure but lacks direct catalyst clarity for REGN specifically — it's ambiguous whether this is a tailwind or just sector noise. (3) Macro backdrop shows elevated 2Y rates (~2σ above trend), which is not directly negative for biotech/pharma but reflects a risk-off undertone that can weigh on high-multiple names like REGN in the final hour. (4) No clear reversal signal — the stock is not described as fading off highs, so momentum appears intact. Balancing a solid intraday move with limited time remaining, ambiguous news linkage, and a mildly unfavorable macro backdrop, this is a borderline momentum hold. Slight edge to continuation given the system's asymmetric payoff structure and absence of a clear fade signal.

100. !Oct 20, 2:46 PMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     REGN is up 2.12% intraday, a meaningful move suggesting real institutional flow. However, several factors temper continuation confidence: (1) Only 60 minutes remain until the forced close, limiting runway for the +3% target to be reached from current levels (would need ~+0.9% more from $798.60 to ~$805.60+). (2) The sole headline references a rare-disease foundation story that is tangentially related to REGN's oncology exposure but lacks direct catalyst clarity for REGN specifically — it's ambiguous whether this is a tailwind or just sector noise. (3) Macro backdrop shows elevated 2Y rates (~2σ above trend), which is not directly negative for biotech/pharma but reflects a risk-off undertone that can weigh on high-multiple names like REGN in the final hour. (4) No clear reversal signal — the stock is not described as fading off highs, so momentum appears intact. Balancing a solid intraday move with limited time remaining, ambiguous news linkage, and a mildly unfavorable macro backdrop, this is a borderline momentum hold. Slight edge to continuation given the system's asymmetric payoff structure and absence of a clear fade signal.

101. ?Oct 14, 11:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

102. !Oct 14, 11:20 AMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

103. ?Oct 14, 11:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

104. !Oct 14, 11:20 AMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

105. ?Oct 14, 10:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

106. !Oct 14, 10:21 AMsignalseverity 0.11

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

107. ?Oct 14, 10:21 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

108. !Oct 14, 10:21 AMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

109. ?Oct 14, 10:20 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     REGN is up 1.82% today, a meaningful but not extreme intraday move. The headline about a Regeneron partner having a 'breakout in sight' provides mild sector-specific tailwind and suggests positive sentiment around the name. The Longleaf Partners portfolio review is neutral/background noise. Macro context shows 5-year forward inflation expectations elevated (~1.5σ above trend), which is a mild headwind for rate-sensitive and high-multiple biotech names — REGN trades at a premium valuation — but this macro factor is not acute enough to strongly fade today's move. With 325 minutes remaining (well over 5 hours), there is ample time for continuation. No reversal signals or fade patterns are indicated. The move is modest in magnitude (sub-2%), which limits both the risk of a mean-reversion flush and the evidence of exceptional conviction. On balance, momentum is modestly positive with no strong reason to expect a fade, placing this in the ordinary continuation range.

110. !Oct 14, 10:20 AMsignalseverity 0.02

     Agent 7 — Day Trader — day_trade_skipped

     REGN is up 1.82% today, a meaningful but not extreme intraday move. The headline about a Regeneron partner having a 'breakout in sight' provides mild sector-specific tailwind and suggests positive sentiment around the name. The Longleaf Partners portfolio review is neutral/background noise. Macro context shows 5-year forward inflation expectations elevated (~1.5σ above trend), which is a mild headwind for rate-sensitive and high-multiple biotech names — REGN trades at a premium valuation — but this macro factor is not acute enough to strongly fade today's move. With 325 minutes remaining (well over 5 hours), there is ample time for continuation. No reversal signals or fade patterns are indicated. The move is modest in magnitude (sub-2%), which limits both the risk of a mean-reversion flush and the evidence of exceptional conviction. On balance, momentum is modestly positive with no strong reason to expect a fade, placing this in the ordinary continuation range.

111. ?Oct 14, 7:00 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

112. !Oct 14, 7:00 AMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

113. ?Oct 14, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

114. !Oct 14, 7:00 AMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

115. ?Oct 13, 4:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

116. !Oct 13, 4:20 PMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

117. ?Oct 13, 4:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

118. !Oct 13, 4:20 PMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

119. ?Oct 13, 3:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

120. !Oct 13, 3:20 PMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

121. ?Oct 13, 3:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

122. !Oct 13, 3:20 PMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

123. ?Oct 13, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

124. !Oct 13, 2:20 PMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

125. ?Oct 13, 2:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

126. !Oct 13, 2:20 PMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

127. ?Oct 13, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

128. !Oct 13, 1:20 PMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

129. ?Oct 13, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

130. !Oct 13, 1:20 PMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

131. ?Oct 13, 12:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

132. !Oct 13, 12:21 PMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

133. ?Oct 13, 12:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

134. !Oct 13, 12:21 PMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

135. ?Oct 13, 11:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

136. !Oct 13, 11:20 AMsignalseverity 0.12

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

137. ?Oct 13, 11:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

138. !Oct 13, 11:20 AMsignalseverity 0.12

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

139. ?Oct 13, 10:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

140. !Oct 13, 10:20 AMsignalseverity 0.13

     Agent 5 — Dip Buyer (Evolving) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

141. ?Oct 13, 10:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

142. !Oct 13, 10:20 AMsignalseverity 0.13

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

143. ?Oct 13, 7:00 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

144. !Oct 13, 7:00 AMsignalseverity 0.11

     Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

145. ?Oct 13, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

146. ?Oct 12, 4:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

147. ?Oct 12, 4:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

148. ?Oct 12, 3:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

149. ?Oct 12, 3:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

150. ?Oct 12, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

151. ?Oct 12, 2:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

152. ?Oct 12, 1:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

153. ?Oct 12, 1:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

154. ?Oct 12, 12:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

155. ?Oct 12, 12:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

156. ?Oct 12, 11:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

157. ?Oct 12, 11:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

158. ?Oct 12, 10:50 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     REGN is up 2.59% intraday with no attributable headline, suggesting institutional flow or sector rotation is driving the move rather than a single catalyst that could fade on exhaustion. The macro context (T10Y3M at 0.99, 1.6σ above trend) is mildly positive for risk assets broadly but is more relevant to banks and recession-sensitive sectors — not directly applicable to large-cap biotech like REGN. With 295 minutes remaining (nearly a full afternoon session), there is ample time for the move to continue into the close. No reversal signals or fade pattern are evident from the data provided. The absence of news is not a disqualifier per the framework. The setup is a straightforward momentum continuation read with no strong counterargument, placing probability modestly above the 0.5 threshold. The bounded risk profile (tight -1.5% stop, +3% target, forced flatten at 3:45 PM) supports taking the trade at this probability level.

159. ?Oct 12, 10:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

160. ?Oct 12, 10:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     REGN is a fundamentally sound large-cap biotech (Dupixent franchise, strong balance sheet) and the 11.3% dip from its 30-day high lacks any confirmed negative catalyst — no damaging headlines, no insider selling, and no unusual put flow. The Health Care sector is exhibiting relative strength (rank 3 of 11, +2.22pts vs SPY over 30 days), suggesting this is idiosyncratic weakness rather than sector-wide selling, which moderately raises concern about company-specific pressure without an identifiable catalyst. However, with no confirmation signals (no insider cluster buys, no unusual call flow, no analyst upgrades) and earnings arriving in 28 days — within the elevated caution window — the setup lacks the asymmetric conviction required for a high-probability buy.

161. ?Oct 12, 7:00 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     REGN is a fundamentally sound large-cap biotech (no guidance cuts, covenant issues, or going-concern language in recent filings), and the Health Care sector is showing relative strength (+2.22pts vs SPY over 30 days), suggesting the drop is idiosyncratic rather than sector-wide. However, earnings are 28 days away (within the 15-30 day headwind window, scoring -1), the 10Y yield at 5.18% is a structural headwind (-1), the drop is only 11.3% (below the 15% mean-reversion threshold), and there are no positive catalysts — no insider buying, no unusual call flow, no news to ground a re-entry thesis. The prior stop-out at $794.19 further underscores that the original momentum thesis has not been revived by new evidence.

162. ▢Sep 29, 8:00 PMjournal

     Agent 4 — Dip Buyer (Frozen) opened long 1 @ $758.25

163. ▣Sep 10, 8:00 PMjournalstop

     Agent 2 — Adaptive closed long 11 @ $781.49 (-$775.94)

     Long trailing stop: close $781.49 ≤ trailing floor $792.39 (peak × 0.93)

164. ▢Sep 1, 8:00 PMjournal

     Agent 2 — Adaptive opened long 11 @ $852.03

165. ▣Aug 30, 8:00 PMjournaltime_stop

     Agent 5 — Dip Buyer (Evolving) closed long 2 @ $794.19 (+$316.32)

     Time stop: held 91 ≥ 90 days

166. ▣Aug 26, 8:00 PMjournalmanual

     Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $827.78 (+$193.24)

     Time stop: held 90 ≥ 90 days

167. ▣Aug 5, 8:00 PMjournalmanual

     Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $767.98 (+$133.44)

     Staged exit (1/2.0): close $768.58 ≥ target $767.21. Selling 1/2 sh, trailing remainder.

168. ▣Aug 4, 8:00 PMjournaltarget

     Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $768.95 (+$134.41)

     Staged exit (1/2.0): close $768.95 ≥ target $767.21. Selling 1/3 sh, trailing remainder.

169. ▣Aug 4, 8:00 PMjournaltarget

     Agent 5 — Dip Buyer (Evolving) closed long 2 @ $768.95 (+$265.84)

     Staged exit (1/2.0): close $768.95 ≥ target $767.21. Selling 2/4 sh, trailing remainder.

170. ▢Jun 25, 8:00 PMjournal

     Agent 7 — Day Trader opened long 4 @ $636.33

171. ▣Jun 25, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 4 @ $631.72 (-$18.44)

     EOD forced close — day trader never carries overnight

172. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 2 @ $636.03

173. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 2 @ $636.03

174. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $634.54

175. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $634.54

176. ▢May 28, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $634.54